Skip to content
Diligo
Create account
Double Bond Pharmaceutical International AB (publ) logoOpenPublic offering

Double Bond Pharmaceutical International AB (publ)

Pharmaceutical development · Uppsala

Double Bond Pharmaceutical develops drug candidates including SI-053, a treatment in preparation for clinical Phase I trials for glioblastoma.

subscription level not reported yet
Instrument
Shares · Class B
Target
SEK 10.2m
Closes
2 Dec 2026
SEK 10.2m
rights issue
45%
of the issue covered by subscription undertakings
SEK 0.11
per Class B share, no brokerage fee
4 clinics
in Germany and the Netherlands for the Phase I trial of SI-0

About the company

Double Bond Pharmaceutical International AB (publ) is a Swedish public pharmaceutical development company founded on 21 November 2014 and registered in Uppsala. The company forms part of a group consisting of the holding company Double Bond Pharmaceutical International AB (publ) and the wholly owned subsidiaries Double Bond Pharmaceutical AB and Drugsson AB. The company's shares are traded on Spotlight Stock Market under the ticker DBP P.

Double Bond develops drug candidates including SI-053, a treatment for glioblastoma that is in preparation for clinical Phase I trials at four German and Dutch clinics under a protocol registered with the European Medicines Agency (EMA). The company has completed preclinical studies of SI-053 with positive results and has conducted a successful Real-World Evidence (RWE) study on Temodex, a prototype of SI-053, which demonstrated a favourable safety profile and validates the mechanism of action in a clinical setting. The company owns an extensive patent portfolio covering SI-053 (Temodex), SA-033, the BeloGal® technology platform and Inofer, as well as proprietary know-how regarding formulation, manufacturing processes and clinical application.

The company has not yet introduced any drug to the market and has not generated any sales revenue. Double Bond is currently holding structured discussions with several potential licensing and commercialisation partners globally. The company's strategy includes the possibility of selling or out-licensing its drug candidates to external parties. Double Bond has obtained the necessary approvals from regulatory authorities and ethics committees in the countries where clinical studies will be conducted.

In January 2025, the company held a first general meeting for liquidation purposes after a balance sheet for liquidation purposes showed that equity was less than half of the registered share capital. Following measures that included a change in accounting policy in the subsidiary Double Bond Pharmaceutical AB to capitalise development expenditure, the share capital was restored and confirmed at a second general meeting in September 2025.

Highlights

  • Completed a successful Real-World Evidence (RWE) study on Temodex (prototype of SI-053) demonstrating a favourable safety profile and validating the mechanism of action in a clinical setting
  • Received necessary approvals from regulatory authorities and ethics committees to conduct clinical Phase I trials of SI-053 at four German and Dutch clinics under a protocol registered with the European Medicines Agency (EMA)
  • Owns an extensive patent portfolio covering SI-053 (Temodex), SA-033, the BeloGal® technology platform and Inofer, plus proprietary know-how in formulation and manufacturing
  • Holding structured discussions with several potential licensing and commercialisation partners globally following positive RWE results
  • Shares traded on Spotlight Stock Market under ticker DBP P (ISIN SE0007185525)

Key facts

Founded
2,014
Registered office
Uppsala, Sweden
Listed on
Spotlight Stock Market (DBP P)
Shares before the issue
222,849,706
New Class B shares, at most
92,854,040
Subscription undertakings
SEK 4.57m (45.1%)
ISIN Class B share
SE0007185525
ISIN subscription right
SE0031088687
ISIN BTA
SE0031088695
LEI
254900U1MWE2YSPREX74

Interview with the founder

The film loads from YouTube when you press play.

Team & board

  • Igor LokotIgor LokotGrundare, President och styrelseledamot
  • Sanna RejnlanderSanna RejnlanderStyrelseordförande
  • Irina ZaitsevaIrina ZaitsevaStyrelseledamot
  • Sergey YanitskySergey YanitskyStyrelseledamot

Company-specific risks

  • The entire investment can be lost. Unlisted shares or shares with limited liquidity can be difficult to sell.
  • Dependence on suppliers, manufacturers and partners: partners may terminate collaboration or fail to meet commitments. The company terminated an agreement with Vivo Biopharma LLC in June 2025 after Vivo failed to fulfil financial milestone obligations, delaying the timeline.
  • No commercial sales or revenue to date: the company has not yet introduced any drug to the market or generated sales revenue, making commercial potential difficult to assess. SI-053 is in preparation for clinical Phase I and may need to be discontinued before marketing authorisation is obtained.
  • Dependence on key individuals: loss of key personnel (employees, board members, consultants, scientific advisors, founders) or failure to recruit qualified staff could delay or prevent the achievement of the company's strategy and development goals.
  • Clinical trial risks: upcoming clinical trials may fail to demonstrate sufficient safety or efficacy, or may produce unexpected results requiring further adaptation or trials, increasing costs and delaying timelines.
  • Future capital requirements are high: the company assesses the likelihood of needing additional capital beyond this rights issue as high. If further financing cannot be secured, the company may be forced to reduce costs, slow operations, enter restructuring or, in the worst case, bankruptcy.
  • Share capital restoration: in January 2025 a first general meeting for liquidation purposes was held after equity fell below half of registered share capital. The capital was restored by September 2025 through accounting changes, but continued financial control and successful capital raising remain necessary.
  • Patent and intellectual property risks: patents have limited terms and may not provide complete commercial protection. Disputes over patent rights or unsuccessful patent applications could result in costs and delays. Third parties may allege infringement, which could impede commercialisation and licensing revenues.
  • Share price volatility and limited liquidity: the share price has historically been volatile and trading volume low. The shares may be difficult to buy or sell at a desired price, and large sales by directors, executives or major shareholders could adversely affect the price.
  • Future dilution: the company has historically financed operations through share issues and may need to do so again. Shareholders who do not participate in future issues (including this rights issue) will be diluted.

Valuation & terms

Subscription period

Subscription opens18 NovToday13 days leftLast day2 Dec
Set-off of outstanding loans: 30%Working capital for ongoing operations, partner discussions, contacts with Key Opinion Leaders outside EU, and scientific and commercial marketing: 50%Manufacturing costs, additional MGMT analysis and preparations for clinical trials of SI-053: 20%
Use of proceeds
  • Set-off of outstanding loans30%
  • Working capital for ongoing operations, partner discussions, contacts with Key Opinion Leaders outside EU, and scientific and commercial marketing50%
  • Manufacturing costs, additional MGMT analysis and preparations for clinical trials of SI-05320%
Pre-money valuation
—
Share price
SEK 0.11
New shares
92,854,040
Minimum ticket
—

Rights issue of up to 92,854,040 Class B shares at SEK 0.11 per share. Existing shareholders receive one subscription right per share held on 16 November 2026; twelve subscription rights entitle the holder to subscribe for five new Class B shares. No lock-up disclosed. Shares not subscribed for with subscription rights may be allotted to other applicants pro rata. Subscription commitments of approximately SEK 4.57 million (45.1% of the issue) have been received; no underwriting. Up to approximately SEK 3 million of subscriptions will be paid by set-off of existing claims against the Company.

The capital raise is run by Aqurat Fondkommission AB, which takes the subscriptions. Diligo does not take subscriptions. Where to subscribe

DocumentsMembers only: Members

Create a free account to see documents.

Members' Q&AMembers only: Members

Create a free account to see members' Q&A.